Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13643MR)

This product GTTS-WQ13643MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13643MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10958MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ2756MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ8510MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ3931MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ4168MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ456MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ6079MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ13972MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW